September 4-7 2018
Boston, MA


Twitter logo for website footers 2

Deep Dive Discussion Day

Pre-Conference Deep Dive Day Agenda

Tuesday, September 4th 2018

In order to drill down on the most crucial topics plaguing CAR-TCR development, we are offering a wide variety of deep dive sessions. These 2 hour sessions provide an enhanced learning experience and are a more intimate opportunity to not only learn from experts on key topic areas, but also to interact with them in a frank, open and peer level environment.

CAR-TCR Discovery Track

CAR-TCR Translation Track

CAR-TCR Manufacturing Track

CAR-TCR Transport,Logistics & Supply Chain Track

CAR-TCR Commercialization Track

9.00 – 11.00am 9.00 – 11.00am 9.00 – 11.00am 9.00 – 11.00am 9.00 – 11.00am

Workshop A:

Optimizing Fuel
Selection for CAR-T Cell Metabolism

Roderick O’ Connor, Instructor,
Center for Cellular Immunotherapies,
University of Pennsylvania School of
Medicine

 

Workshop B:

How will gene editing take off-the-shelf allogeneic cell therapies to the next stage in the future?

David Sourdive, Executive Vice
President Technical Operations,
Cellectis

Workshop C:

Vector Production
Challenges for Multi-Product Cell
Therapy Programs

Steven Feldman, Director, Surgery
Branch Vector Production Facility,
National Cancer Institute (NCI) in NIH

Workshop D:

Manufacturing
and Supply Chain Strategies for
Engineered T Cell Therapies

Bruce Levine, Founding Director
of the Clinical Cell and Vaccine
Production Facility (CVPF), University
of Pennsylvania

Workshop E:

IP and Licensing:
Navigating the Landscape

Shawn Foley, Attorney, Intellectual
Property, Burns & Levinson
12.00 – 2.00pm 12.00 – 2.00pm 12.00 – 2.00pm 12.00 – 2.00pm 12.00 – 2.00pm

Workshop F:

Bi-specific Adaptor
Controlled CAR-T Cell Therapy for Solid
and Liquid Tumors

Chris Leamon, Vice President of
Research, Endocyte

Workshop G:

Optimizing the
Predictive Value of Preclinical
Models for Translation of Adoptive Immunotherapies into Human Trials

Avery Posey, Instructor-level Faculty,
University of Pennsylvania

Workshop H:

Specifications for
Release Criteria

Therese Choquette, Analytical Project
Leader, Cell and Gene Therapy
Development and Manufacturing,
Novartis

Workshop I:

Manufacturing Of
TCR Based T Cells For Solid Tumors:
Experience And Lessons Learned

Ali Mohamed, Vice President, CMC,
Immatics US Inc.

Workshop J:

Innovation in
Reimbursement for Cellular
Therapies: a US Perspective

Edmund Pezalla, CEO & Founder of
Enlightenment Bioconsult, LLC

 

2.00 – 3.00pm Afternoon Refreshments & Debrief
3.00 – 5.00pm 3.00 – 5.00pm 3.00 – 5.00pm 3.00 – 5.00pm 3.00 – 5.00pm

Workshop K:

Engineering T Cells for
Solid Tumor Applications, The End of
The Beginning

Rick Morgan, Vice President of
Immunotherapy, bluebird bio

Workshop L:

The Challenges of
Correlative and Release Test Assays for
Evaluating Gene Edited Human Cell Products

Simon Lacey, Director Translational and
Correlative Studies Laboratory, Center
for Cellular Immunotherapies, UPenn

Workshop M:

Confronting Analytical
Challenges of Chimeric Antigen
Receptor T Cell

Eileen Higham, Head of Analytical
and Process Development, Juno
Therapeutics

Workshop N:

Delivering Next
Generation CAR-T Therapies

Rodney Rietze, Enabling Technology and
Strategic Development, Novartis

Workshop O:

Investigating the Regulatory Landscape of CAR-T Therapy

Gopalan Narayanan, Vice President,
Disruptive Biologics
 5.00pm Evening Refreshments & Debrief